[
    [
        {
            "time": "2019-03-12",
            "original_text": "BioNTech hires banks for IPO worth up to $800 million - sources",
            "features": {
                "keywords": [
                    "IPO",
                    "BioNTech",
                    "$800 million"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-03-12",
            "original_text": "Biontech stock offering could be worth as much as $800 million-sources",
            "features": {
                "keywords": [
                    "stock offering",
                    "Biontech",
                    "$800 million"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-03-12",
            "original_text": "Option trading opportunities in Pfizer & Sirius XM",
            "features": {
                "keywords": [
                    "option trading",
                    "Pfizer",
                    "Sirius XM"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "media"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 5,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-03-12",
            "original_text": "Pfizer's Herceptin Biosimilar Trazimera Gets FDA Approval",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Herceptin",
                    "FDA Approval"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-03-12",
            "original_text": "Pfizer's (PFE) Kidney Cancer Drug Combo Gets EMA's Validation",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Kidney Cancer",
                    "EMA Validation"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-03-12",
            "original_text": "See what the IHS Markit Score report has to say about Pfizer Inc.",
            "features": {
                "keywords": [
                    "IHS Markit Score",
                    "Pfizer"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 5,
                "Sentiment": 4,
                "Importance": 4,
                "Impact": 3,
                "Duration": 2,
                "Entity_Density": 6,
                "Market_Scope": 2,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 4
            }
        },
        {
            "time": "2019-03-12",
            "original_text": "Health Care Sector Update for 03/12/2019: ZFGN, AKBA, HEXO, JNJ, PFE, ABT, MRK, AMGN",
            "features": {
                "keywords": [
                    "Health Care Sector",
                    "ZFGN",
                    "AKBA",
                    "HEXO",
                    "JNJ",
                    "PFE",
                    "ABT",
                    "MRK",
                    "AMGN"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-03-12",
            "original_text": "Why Novartis is a Top 10 SAFE International Dividend Stock (NVS)",
            "features": {
                "keywords": [
                    "Novartis",
                    "SAFE",
                    "International Dividend Stock"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]